Bovine Respiratory Disease

Tim Hammerich

News Reporter

Yesterday we reported on how companies are tapping into the microbiome to find new solutions to animal health and nutrition. Specifically, we featured Resilient Biotics, who is isolating microbes that are beneficial for bovine respiratory disease. CEO Chris Belnap says this niche adds up to a big market.

Belnap… “The cost of the problem is extremely high, and the market opportunity is incredibly high, and that's one of the reasons that we identified this as the lead problem that we should work on from the outset. You know, in terms of what it costs the cattle industry in North America, it's about $3 billion per year. And that includes cost of treatments for antibiotics, for vaccines. It includes cost of labor of managing sick animals. Once an animal goes through a bout of respiratory disease, it generally doesn't perform as well. So there there's a cost to that as well. The animal is going to be worth less at the end.”

Belnap says as far as treatment is concerned, bovine respiratory disease is one of the largest single treatment markets that exists in animal health.

Belnap… “In North America, it's getting close to about a billion per year in treatment opportunity. And that's largely because of today treatments with vaccines and antibiotics. It really represents a massive opportunity in animal health.”

To learn more about this product and the microbiome approach to these solutions you can visit their website: www.resilientbiotics.com.